DiaMedica Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A synthetic KLK1 protein therapy is advancing in trials for preeclampsia and stroke, showing strong safety and efficacy signals, with multiple clinical readouts expected through next year. The company is well-funded, targeting large unmet needs, and leverages extensive Asian clinical data.
Fiscal Year 2025
-
Significant clinical progress was made in 2025, with DM199 showing strong efficacy and safety in preeclampsia and stroke trials. Financial position strengthened, supporting operations through 2027, and regulatory milestones were achieved for global trial expansion.
-
DM199 showed strong interim results in preeclampsia, with rapid blood pressure reduction and a favorable safety profile. Cash reserves increased to $55.3M, supporting operations into 2027, while clinical trial progress continues in both preeclampsia and stroke.
-
Recent phase II data for DM199 in preeclampsia showed significant blood pressure reduction and improved placental perfusion, with a strong safety profile and no placental transfer. The program targets a high unmet need in early-onset preeclampsia, with pivotal trials and U.S. expansion planned.
-
Positive interim results for DM199 in preeclampsia and stroke programs drove clinical progress, supported by a $30M private placement extending cash runway into 2027. Enrollment in the REMEDY-2 stroke trial is advancing, and a U.S. Phase II-B preeclampsia trial is in preparation.
-
Interim phase II results for DM199 in severe preeclampsia showed strong safety, no placental transfer, and significant, dose-dependent blood pressure reductions. Enhanced placental perfusion and promising investigator observations support further study expansion and potential for disease modification.
-
Preeclampsia remains a major unmet need with no approved therapies, causing significant maternal and neonatal risks. DM199, a novel protein therapy, aims to reduce blood pressure, improve endothelial health, and avoid fetal exposure, with early clinical trials focusing on safety, efficacy, and placental transfer.
-
DM199 is advancing in pivotal trials for both ischemic stroke and pre-eclampsia, with key proof-of-concept data for pre-eclampsia expected by early July. The drug’s unique mechanism and safety profile address significant unmet needs, and upcoming events will further detail trial progress.
-
Clinical programs in pre-eclampsia and stroke advanced, with key trial milestones approaching. Cash runway extends into Q3 2026, and R&D expenses are set to rise as trials expand. Pre-eclampsia top-line results are expected by mid-July.
Fiscal Year 2024
-
Clinical programs for DM199 in preeclampsia and stroke advanced, with strong safety and enrollment progress. Cash runway extends into Q3 2026, and interim ReMEDy2 analysis is now expected in 1H 2026. Recent protocol changes and industry developments may boost trial enrollment.
-
Progress continues on stroke and pre-eclampsia programs, with protocol updates expected to accelerate ReMEDy2 trial enrollment and improve commercial prospects. Cash runway extends to Q3 2026, and DM199's expanded target population could add over $1 billion in U.S. revenue potential.
-
ReMEDy2 trial enrollment is progressing, with 13 sites activated and full interim analysis enrollment targeted by Q1 2025. Cash runway now extends into Q3 2026 after a $11.8M private placement. Preeclampsia program advances, with top-line results expected in H1 2025.
-
Plans to expand DM199 into preeclampsia target a major unmet need with a capital-efficient phase II trial, leveraging a strong safety profile and rapid proof-of-concept timeline. Recent funding extends cash runway into 2026, supporting both stroke and preeclampsia programs.